Critical Therapeutics presents Zyflo study results for the treatment of asthma

By Lisa Kerner

Erie, Pa., May 23 - Critical Therapeutics, Inc. presented two scientific posters related to its asthma drug Zyflo (zileuton tablets) at the 2006 International Conference of the American Thoracic Society in San Diego.

The first poster is a retrospective analysis of a randomized, placebo-controlled, double-blind, parallel-group study examining the safety and efficacy of two doses of Zyflo in 401 asthma patients, according to a company news release.

Patients were randomized to one of three treatment groups: the prescribed dose of zileuton 600 mg four times daily, zileuton 400 mg four times daily or a placebo. The company said quality-of-life scores increased in both subgroups for asthmatics on zileuton 600 mg as measured by the Asthma Quality of Life Questionnaire.

In the second poster, researchers show that Zyflo plays a key role in inhibiting the migration, aggregation and adhesion of two types of white blood cells, eosinophils and neutrophils, in response to leukotrienes in animal models.

Zileuton reduced the infiltration of polymorphonuclear neutrophils and also reduced systemic immunoglobulin E (IgE), according to the release.

Based in Lexington, Mass., Critical Therapeutics is focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.